Evidence map›Paper›PMID 41827857›Full record

ArticleCells2026

Lack of Oxygen and/or Glucose Differentially Potentiates Aβ40

Ashley Carey, Tetyana Buzhdygan, Silvia Fossati

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ashley CareyAlzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Tetyana BuzhdyganAlzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Silvia FossatiAlzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.ORCID 0000-0002-2047-222X

Funding

Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factorsR01NS104127 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI FOSSATI, SILVIA · 2018 to 2022
$3.0M
Targeting carbonic anhydrases in Alzheimer's diseaseR01AG062572 · NIA · TEMPLE UNIV OF THE COMMONWEALTH · PI FOSSATI, SILVIA · 2019 to 2023
$2.3M
NIA NIH HHS R01 AG062572NIH HHS NHLBI T32 Training GrantNIH HHS R01AG062572NIH HHS R01NS104127NINDS NIH HHS R01 NS104127PA Department of Health PA CureThe Alzheimer's Association AARG-20-685,663The Karen Toffler Charitable Trust Toffler Scholar
6 · The paper itself

Abstract

Cerebrovascular damage/dysfunction promote cerebral hypoperfusion early within Alzheimer's Disease (AD). Cerebral hypoperfusion is also a common consequence of cardiovascular risk factors/diseases, typically manifesting in midlife when AD pathology initiates, and contributing to AD onset/progression. We demonstrated that AβQ22 (vasculotropic Dutch mutant) and Aβ42 promote cerebral endothelial cell (cEC) apoptosis, barrier permeability, and angiogenic impairments. Prior research indicates hypoperfusion promotes analogous EC dysfunction. Aβ accumulates within a hypoperfused environment in AD, but whether Aβ exposure of cECs under hypoperfusion potentiates dysfunction through activation of shared molecular mechanisms remains unknown. We treated cECs with Aβ40-Q22/Aβ42, glucose deprivation (GD), or both under normoxia or hypoxia. Cell death, barrier dysfunction/permeability, proinflammatory activation, and angiogenesis impairment were evaluated. Overall, GD and/or hypoxia potentiated Aβ-induced cEC death, barrier dysfunction, inflammatory activation, and angiogenesis/wound healing failure. Hypoperfusion specifically exacerbated AβQ22-mediated cEC apoptosis, TEER/ZO1 decreases, ICAM1/IL6/IL8 upregulation, monocyte migration, and wound healing impairments. Differentially, hypoperfusion strongly potentiated Aβ42-mediated necrosis and MMP2/pClaudin-5/IFNγ/IL12p70 increases. GD exerted stronger increases in caspase-3 activation/apoptosis and MMP2/ICAM1 expression, while hypoxia increased necrosis and ZO1/pro-angiogenic proteins. This study reveals specific, selective mechanisms that hypoxia/GD and amyloidosis mutually activate to produce cEC dysfunction, highlighting new molecular targets against vascular pathology in AD/CAA comorbid with hypoperfusion.

Indexed as

Amyloid beta-PeptidesAngiogenesisBlood-Brain BarrierEndothelial CellsGlucoseNeovascularization, PathologicOxygenPeptide FragmentsAlzheimer DiseaseAnimalsApoptosisCell DeathCell HypoxiaHumansAmyloid beta-Peptidesamyloid beta-protein (1-42)GlucoseOxygenPeptide FragmentsAlzheimer’s Diseaseamyloid betacerebral endothelial cell dysfunctioncerebral hypoperfusionoxygen glucose deprivation

Identifiers

PMID41827857
PMCPMC12984660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.